Browse by Medical Category
Accepting New Patients
Currently, Dr.Chen divides his time between patient care, clinical research and program administration with a focus on patients undergoing bone marrow/stem cell transplantation. He invites you to contact him directly with any questions. New patients please call 617-724-6587
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Yi-Bin Chen grew up in New Jersey. He majored in molecular biophysics and biochemistry, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital including an additional year as Chief Resident. This was followed by a fellowship in hematology / oncology at the Dana-Farber Partners combined program. In 2008, he joined the staff of the Blood & Marrow Transplant (BMT) Program at the MGH Cancer Center, has served as Director of Clinical Research since 2012 and was named overall Program Director in 2016. His interests mainly revolve around improving the outcomes of patients underoing autologous and allogeneic stem cell transplantion. He has led original clinical trials involving all aspects of BMT including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and 2 children.
Dr. Chen is the Director for the BMT program at MGH. His research interests mainy revolve around improving the outcomes for patients undergoing autologous and allogeneic stem cell transplantation. He serves as institution and overall principal investigator for many clinical trials. MGH is an active participant in several national collaborative group trials, specifically from Alliance and the BMT CTN. In addition, Dr. Chen currently lead the following investigative efforts: 1. Use of brentuximab vedotin to target CD30 in the treatment of acute graft-vs-host disease (GVHD)2. Inhibition of the FLT3 mutation after allogeneic transplant for patients with FLT3-ITD mutated AML
3. Use of third-party fecal microbiota transplantation to restore microbiome diversity in recipients of BMT
4. Use of vedolizumab for the prevention and treatment of acute intestinal GVHD5. Combined bone marrow and kidney transplantation using partially matched family donorsDr. Chen invites you to contact him directly to inquire about the latest clinical investigations available at MGH.
Back to Top